Molecular basis for the protective effects of low-density lipoprotein receptor-related protein 1 (LRP1)-derived peptides against LDL aggregation.

Arthropod Proteins / blood Humans Lipoproteins, LDL / chemistry Low Density Lipoprotein Receptor-Related Protein-1 / chemistry Oligopeptides / blood Peptides / metabolism Phospholipases A2 / metabolism Phospholipids / chemistry Protein Binding Sphingomyelin Phosphodiesterase / chemistry Static Electricity
ApoB-100 LRP1-derived peptides Lipoprotein aggregation SMase, PLA(2), atherosclerosis

Journal

Biochimica et biophysica acta. Biomembranes
ISSN: 1879-2642
Titre abrégé: Biochim Biophys Acta Biomembr
Pays: Netherlands
ID NLM: 101731713

Informations de publication

Date de publication:
01 07 2019
Historique:
received: 20 01 2019
revised: 09 04 2019
accepted: 01 05 2019
pubmed: 12 5 2019
medline: 15 2 2020
entrez: 12 5 2019
Statut: ppublish

Résumé

Aggregated LDL is the first ligand reported to interact with the cluster II CR9 domain of low-density lipoprotein receptor-related protein 1 (LRP1). In particular, the C-terminal half of domain CR9, comprising the region Gly

Identifiants

DOI: 10.1016/j.bbamem.2019.05.003 PMID: 31077676
pubmed: 31077676
pii: S0005-2736(19)30094-X
doi: 10.1016/j.bbamem.2019.05.003
pii:
doi:

Substances chimiques

Arthropod Proteins 0
LRP1 protein, human 0
Lipoproteins, LDL 0
Low Density Lipoprotein Receptor-Related Protein-1 0
Oligopeptides 0
Peptides 0
Phospholipids 0
prolyl-aspartyl-histidyl-histidyl-methionyl-methionyl-tyrosyl-phenylalaninamide 0
Phospholipases A2 EC 3.1.1.4
Sphingomyelin Phosphodiesterase EC 3.1.4.12

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1302-1316

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Aleyda Benitez-Amaro (A)

Group of Lipids and Cardiovascular Pathology, Biomedical Research Institute Sant Pau (IIB Sant Pau), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), Barcelona, Spain.

Chiara Pallara (C)

Iproteos S.L., Barcelona Science Park (PCB), Barcelona, Spain.

Laura Nasarre (L)

Group of Lipids and Cardiovascular Pathology, Biomedical Research Institute Sant Pau (IIB Sant Pau), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Andrea Rivas-Urbina (A)

Cardiovascular Biochemistry Group, Research Institute of the Hospital de Sant Pau (IIB Sant Pau), Barcelona, Spain.

Sonia Benitez (S)

Cardiovascular Biochemistry Group, Research Institute of the Hospital de Sant Pau (IIB Sant Pau), Barcelona, Spain.

Angela Vea (A)

Group of Lipids and Cardiovascular Pathology, Biomedical Research Institute Sant Pau (IIB Sant Pau), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Olga Bornachea (O)

Group of Lipids and Cardiovascular Pathology, Biomedical Research Institute Sant Pau (IIB Sant Pau), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), Barcelona, Spain.

David de Gonzalo-Calvo (D)

Group of Lipids and Cardiovascular Pathology, Biomedical Research Institute Sant Pau (IIB Sant Pau), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), Barcelona, Spain; CIBER Enfermedades Cardiovasculares (CIBERcv), Spain.

Gabriel Serra-Mir (G)

Protein Design and Immunotherapy Group, Departament de Bioquímica i Biologia Molecular, Facultat de Biociències, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain.

Sandra Villegas (S)

Protein Design and Immunotherapy Group, Departament de Bioquímica i Biologia Molecular, Facultat de Biociències, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain.

Roger Prades (R)

Iproteos S.L., Barcelona Science Park (PCB), Barcelona, Spain.

José Luís Sanchez-Quesada (JL)

Cardiovascular Biochemistry Group, Research Institute of the Hospital de Sant Pau (IIB Sant Pau), Barcelona, Spain; CIBER DIABETES y Enfermedades Metabólicas Asociadas (CIBERdem), Spain.

Cristina Chiva (C)

Proteomics Unit, Centre de Regulació Genòmica, Barcelona Institute of Science and Technology, Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain.

Eduard Sabido (E)

Proteomics Unit, Centre de Regulació Genòmica, Barcelona Institute of Science and Technology, Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain.

Teresa Tarragó (T)

Iproteos S.L., Barcelona Science Park (PCB), Barcelona, Spain.

Vicenta Llorente-Cortés (V)

Group of Lipids and Cardiovascular Pathology, Biomedical Research Institute Sant Pau (IIB Sant Pau), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), Barcelona, Spain; CIBER Enfermedades Cardiovasculares (CIBERcv), Spain. Electronic address: Cllorente@santpau.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines d'arthropode › Molecular basis for the protective effects of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Molecular basis for the protective effects of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Lipoprotéines › Lipoprotéines LDL › Molecular basis for the protective effects of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux lipoprotéines › Récepteurs aux lipoprotéines LDL › Protéines apparentées au récepteur LDL › Protéine-1 apparentée au récepteur des LDL › Molecular basis for the protective effects of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Oligopeptides › Molecular basis for the protective effects of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Molecular basis for the protective effects of...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Esterases › Carboxylic ester hydrolases › Phospholipases A › Phospholipases A2 › Molecular basis for the protective effects of...
questionsmedicales.fr › Lipides › Lipides membranaires › Phospholipides › Molecular basis for the protective effects of...
questionsmedicales.fr › Métabolisme › Liaison aux protéines › Molecular basis for the protective effects of...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Esterases › Phosphodiesterases › Sphingomyeline phosphodiesterase › Molecular basis for the protective effects of...
questionsmedicales.fr › Phénomènes physiques › Phénomènes magnétiques › Phénomènes électromagnétiques › Électricité › Électricité statique › Molecular basis for the protective effects of...